Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Elicio Therapeutics (ELTX) Gross Profit (2020 - 2021)

Elicio Therapeutics filings provide 2 years of Gross Profit readings, the most recent being $24.7 million for Q4 2021.

  • On a quarterly basis, Gross Profit rose 1149.36% to $24.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $27.1 million, a 1553.97% increase, with the full-year FY2022 number at $2.3 million, down 91.5% from a year prior.
  • Gross Profit hit $24.7 million in Q4 2021 for Elicio Therapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $24.7 million in Q4 2021 to a low of -$2.4 million in Q4 2020.